Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. is asking shareholders to vote at its virtual-only 2026 annual meeting on three items: electing 11 directors for one-year terms, ratifying Deloitte & Touche LLP as auditor for 2026, and approving on an advisory basis executive compensation.
The proxy highlights the second year of MetLife’s five-year New Frontier strategy, targeting double-digit adjusted EPS growth, 15–17% adjusted ROE, a 100 basis point reduction in the direct expense ratio from 12.3%, and more than $25 billion in free cash flow over 2025–2029. In 2025, net income available to common shareholders was $3,173 million or $4.71 per diluted share, compared with $4,226 million or $5.94 in 2024, while ROE was 12.9% versus 16.9%.
The filing describes strong pay‑for‑performance alignment, with most 2025 total compensation for named executive officers variable and 70% of stock-based long‑term incentives tied to relative total shareholder return and adjusted ROE. It also details board refreshment, governance practices, risk and cybersecurity oversight, and a fully independent board chair structure.
MetLife, Inc. is providing preliminary information on its variable investment income for the quarter ended March 31, 2026 ahead of its full quarterly results. The company estimates pre-tax variable investment income of $475 million to $525 million, compared with full-year 2026 guidance of approximately $1.6 billion pre-tax.
Variable investment income reflects results from private equity, real estate and other funds, as well as prepayment fees. The figures are unaudited, based on preliminary data, and may differ materially once financial closing procedures are complete. MetLife emphasizes that this information is not a substitute for U.S. GAAP financial statements and includes forward-looking statements subject to risk factors described in its SEC filings.
Harris Carla A reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carla A. Harris received an award of 721 shares of common stock as part of non-management director compensation. The shares were valued at $71.17 each and are being deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, Harris directly holds 10,485 shares of MetLife common stock.
Seitz Michelle reported acquisition or exercise transactions in this Form 4 filing.
METLIFE INC director Michelle Seitz received a grant of 721 shares of Common Stock as part of her board compensation. The shares were awarded at a stated price of $0.00 per share as a non-management director retainer paid in MetLife common stock. Following this award, she holds 994 shares directly.
Kennard William E reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director William E. Kennard received a grant of 721 shares of MetLife common stock on April 1, 2026, as part of non‑management director compensation. The shares were valued at $71.17 each and he elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this award, Kennard is reported as beneficially owning 46,501 shares of MetLife common stock directly, and an additional 10 shares are held indirectly in the MetLife Policyholder Trust that holds stock allocated to eligible policyholders.
HUBBARD ROBERT GLENN reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Robert Glenn Hubbard received a grant of 1,248 shares of common stock valued at $71.17 per share as part of non-management director compensation. This award reflects retainer fees that are paid in MetLife stock rather than cash.
The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the shares are credited rather than immediately delivered. Following this grant, he holds 105,878 shares of MetLife common stock directly.
MORRISON DENISE M reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Denise M. Morrison received a grant of 721 shares of MetLife common stock on 2026-04-01 as part of non-management director compensation arrangements. The shares were awarded at $0.00 per share, reflecting stock-based fees rather than a market purchase.
After this award, Morrison directly holds 34,711 shares of MetLife common stock. A portion of MetLife’s non-management director retainer fees is paid in common stock, so this transaction represents routine equity compensation rather than an open-market trade.
Mumenthaler Christian Stephane reported acquisition or exercise transactions in this Form 4 filing.
METLIFE INC director Christian Stephane Mumenthaler received an equity grant of MetLife common stock as part of his board compensation. On this Form 4, he was awarded 721 shares of common stock at $71.17 per share, increasing his directly reported holdings to 2,846 shares. The footnote explains that MetLife pays a portion of non-management director retainer fees in common stock and that he elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the compensation is taken in stock units rather than immediate cash.
MCKENZIE DIANA reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Diana McKenzie received a grant of 721 shares of common stock, valued at $71.17 per share, as part of non-management director retainer fees. Following this award, she directly holds 24,472 shares. She elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Glaser Daniel S reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Daniel S. Glaser received an equity award of 721 shares of common stock, valued at $71.17 per share. The award represents a portion of his non-management director retainer fees paid in stock. He elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this grant, Glaser directly holds 2,101 shares of MetLife common stock. In addition, 198 shares are held indirectly in a GRAT, reflecting an estate-planning vehicle associated with his holdings.